Advertisement

Dual Antiplatelet and Glycoprotein Inhibitors in Emergency PCI

  • Alan Yean Yip Fong
  • Hwei Sung Ling
Open Access
Chapter

Abstract

Platelet inhibition remains the core pharmacotherapy component in patients undergoing emergency or primary percutaneous coronary interventions (PCI). This can be achieved using a number of intravenous and oral preparations. Intravenous (iv) antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the only available intravenous P2Y12 inhibitor, cangrelor. Available oral agents include aspirin and various P2Y12 inhibitors or their analogues. These are usually used in combination with the intention to maintain dual antiplatelet therapy (DAPT) for a period of time (generally up to 12 months) after the index PCI procedure.

8.1 Introduction

Platelet inhibition remains the core pharmacotherapy component in patients undergoing emergency or primary percutaneous coronary interventions (PCI). This can be achieved using a number of intravenous and oral preparations. Intravenous (iv) antiplatelets include various glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors and the only available intravenous P2Y12 inhibitor, cangrelor. Available oral agents include aspirin and various P2Y12 inhibitors or their analogues. These are usually used in combination with the intention to maintain dual antiplatelet therapy (DAPT) for a period of time (generally up to 12 months) after the index PCI procedure.

Understanding and appropriate use of antiplatelet agents are vital in optimizing clinical outcomes of patients with acute coronary syndromes, particularly in the emergency setting where the patient may be naïve to all pharmacological agents. In this review, an overview on antiplatelet therapy for patient needing emergency PCI is described, including evidence from important clinical trials and suggested antiplatelet therapy regimens by published clinical practice guidelines.

8.2 Aspirin

Aspirin (acetylsalicylic acid) (≥75 mg daily) permanently inhibits platelet-dependent cyclooxygenase 1 (COX-1) enzyme and consequently preventing synthesis of and thromboxane A2 (TXA2), which is a powerful promoter of platelet aggregation [1]. At higher doses, aspirin inhibits COX-2 which offers analgesic and antipyretic effects by blocking production of prostaglandin. Aspirin in a broad range of patients has been shown to offer clinically important benefits on protection from coronary artery disease (CAD). This predominantly appears related to antiplatelet effects, although the drug may also play a role in reducing atherosclerosis by blocking COX-dependent vasoconstrictors and prevent oxidation of low density lipoprotein. Importantly, aspirin has become a central component of the antiplatelet regimen both for patients with established CAD and those undergoing PCI procedures.

8.2.1 Evidence of Aspirin in Myocardial Infarction and PCI

Major studies indicating a central role for aspirin in patients with acute MI and undergoing emergency revascularization include:
  • International Study of Infarct Survival (ISIS-2) [2]

    This study was performed in the thrombolysis era but demonstrated a headline 23% reduction of mortality rate among patients with MI with a near to 50% reduction of nonfatal reinfarction or stroke.

  • Meta-analysis of aspirin usage for prevention of stroke, myocardial infarction, and death among high-risk patients [3]

    This study from the Antithrombotic Trialists’ Collaboration showed a 53% reduction of death and vascular events in those underwent coronary angioplasty.

  • Aspirin in prevention of restenosis after PCI [4]

    This study showed that in addition to protection from stent thrombosis, aspirin offered a significant reduction of stent restenosis rate after PCI.

8.2.2 Aspirin Dosing

Consensus with regard to dosing of aspirin before and after PCI (including primary PCI) has been established and recommended as follows [5]:
  • Loading (prior to PCI)

    Tablet 300–325 mg stat dose—if not on chronic aspirin therapy, at least 2 h before PCI

    Tablet 81–325 mg stat dose—if already on chronic aspirin therapy

  • Maintenance therapy (post PCI)

    Tablet 75–162 mg OD—to continue indefinitely

8.3 P2Y12 Inhibitors

The P2Y12 receptor plays a key role in the platelet activation process. Adenosine diphosphate (ADP) interacts with the platelet P2Y12 receptor stimulating activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. In turn, activation of the GP2b3a receptor results in enhanced platelet degranulation and thromboxane production, driving platelet aggregation [6].

Various P2Y12 inhibitors are available. Clopidogrel and prasugrel are thienopyridine prodrugs that must undergo cytochrome P450-mediated conversion to the active metabolite which then covalently bond to the P2Y12 receptor, thus inhibiting platelet activation. In contrast, ticagrelor and cangrelor are direct-acting platelet inhibitors which do not need activation. These agents are thus more potent and have more rapid onset of action.

8.3.1 Evidence for P2Y12 Inhibitor in MI and PCI

  • CURE (PCI-CURE) [7]

    This trial showed a significant reduction of cardiovascular death and myocardial infarction post PCI using clopidogrel.

  • TRITON-TIMI 38 [8]

    This trial showed a significant reduction of cardiovascular death, nonfatal myocardial infarction, and stroke using prasugrel among patients with high-risk ACS undergoing PCI. Of note, patients with prior stroke, transient ischemic attack (TIA), age > 75, and weight < 60 kg had no net benefit.

  • PLATO [ 9 ]

    This trial showed a reduction of composite death from vascular causes, MI, and stroke with use of ticagrelor. Of note, patients with prior stroke, TIA which led to net harm, age > 75, and weight < 60 kg had no net benefit.

8.3.2 P2Y12 Inhibitor Dosing

  • Clopidogrel
    • Loading (prior to PCI)
      • Tablet 150–300 mg stat dose

    • Maintenance therapy
      • Tablet 75–100 mg OD

  • Prasugrel
    • Loading (prior to PCI)
      • Tablet 60 mg stat dose

    • Maintenance therapy
      • Tablet 10 mg OD

      • Tablet 5 mg OD (if body weight < 60 kg)

  • Ticagrelor
    • Loading (prior to PCI).
      • Tablet 180 mg stat dose

    • Maintenance therapy
      • Tablet 90 mg BD

8.4 Glycoprotein IIb/IIIa Inhibitors

GPIIb/IIIa inhibitors directly target the platelet glycoprotein IIb/IIIa (GPIIb/IIIa) receptor. This receptor is the most abundant integrin found on the surface of platelets and is composed of two separate subunits, αIIb (GPIIb) and β3 (GPIIIa). GPIIb/IIIa inhibitors prevent binding of primarily fibrinogen, but various other ligands also, hence, inhibit the aggregation of platelets [10]. Various agents are available: Abciximab is a monoclonal antibody. Eptifibatide is a synthetic cyclic heptapeptide. Tirofiban is a nonpeptidal antagonist to glycoprotein IIb/IIIa receptor.

8.4.1 Evidence for GPIIb/IIIa Inhibitors in MI and PCI

  • Guidance on the Use of Glycoprotein IIb/IIIa Inhibitors in the Treatment of Acute Coronary Syndrome [10]

Review of multiple trials showed statistically significant benefit in GPIIb/IIIa treatment groups in terms of composite outcome of death, subsequent MI, and revascularization.
  • Evaluation of 7e3 for Prevention of Ischemic Complication (EPIC) [ 11 ]

Usage of abciximab during coronary angioplasty after presentation with high-risk unstable angina showed significant reduction in composite death, nonfatal MI, repeat coronary artery bypass grafting (CABG), repeat PCI for recurrent ischemia, or requirement for a coronary stent after balloon angioplasty.
  • Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) [ 12 ]

Usage of eptifibatide in patient with ST changes and MI (but not persistent ST elevation) together with aspirin and intravenous heparin, via infusion for up to 96 h, significantly reduces composite of death and nonfatal myocardial infarction within 30 days from index event.
  • The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM PLUS) [ 13 ]

Usage of tirofiban with heparin infusion in patient with acute myocardial infarction for up to 72 h showed significant decrease of 7 days to 30 days composite death, recurrent myocardial infarction.

8.4.2 Dosing

  • Abciximab
    • Bolus of 0.25 mg/kg intravenous

    • Infusion at 0.125 μg/kg/min (maximum 10ug/min) for 12 h

  • Eptifibatide
    • Double bolus of 180 μg/kg intravenous (given at 10-min interval)

    • Infusion 2.0 μg/kg/min for up to 18 h

  • Tirofiban
    • Bolus of 25 μg/kg over 3 min

    • Infusion at 0.15 μg/kg/min for up to 18 h

    • DAPT and glycoprotein IIb/IIIa inhibitor in emergency PCI

8.5 Recommended Treatment Algorithms from Consensus Guidelines [14, 15]

  1. 1.

    A potent, faster onset and superior clinical efficacy P2Y12 inhibitor (prasugrel or ticagrelor) is recommended ideally prior to (or at least at the time of) PCI.

     
  2. 2.

    Ticagrelor is recommended as P2Y12 inhibitor of choice on top of aspirin in patients with ACS.

     
  3. 3.

    Ticagrelor should not be used in patient with previous intracranial hemorrhage or ongoing bleeds or on oral anticoagulants.

     
  4. 4.

    Prasugrel should not be used in patient with previous intracranial hemorrhage, previous ischemic stroke or transient ischemic attack, or ongoing bleeds or on oral anticoagulants. Prasugrel is generally not recommended in patient >75 years old or weighing <60 kg.

     
  5. 5.

    In cases prasugrel is used for patient >75 years old or weighing <60 kg, a dose of 5 mg OD should be used.

     
  6. 6.

    When none of the ticagrelor or prasugrel can be used, clopidogrel can be the choice of P2Y12 inhibitor.

     
  7. 7.

    Switching from clopidogrel to either ticagrelor or prasugrel in acute setting need not consider prior clopidogrel timing and dosing (Fig. 8.1).

     
  8. 8.

    Switching in between ticagrelor and prasugrel or from either one to clopidogrel in acute setting requires 24-h lapse since the last dose (Fig. 8.1).

     
  9. 9.

    Bleeding risk can be assessed using risk model, e.g., PRECISE-DAPT and DAPT score. Bleeding risk decides duration of DAPT (Fig. 8.2).

     
  10. 10.
    Suggested duration of DAPT (Fig. 8.3):
    1. (a)
      Acute coronary syndrome receiving PCI
      • At least 12 months of DAPT (aspirin and a P2Y12 inhibitor) is recommended.

      • Six months of DAPT should be considered if there is high bleeding risk; with emerging data for abbreviated DAPT with certain stents, even earlier cessation may be possible.

      • Extension of DAPT >12 months may be considered if no bleeding complication during initial treatment.

       
    2. (b)
      Benefits and risks of extended DAPT (18–36 months)
      • Absolute decrease in risk of instent thrombosis, myocardial infarction, and major adverse cardiac events by 1–2%.

      • Absolute increase in bleeding complications by 1%.

      • More benefits are seen in patient with ACS rather stable IHD.

       
     
  11. 11.
    Types of stent and its duration:
    1. (a)

      Shorter duration (3–6 months) may be reasonable in patients treated with newer-generation stents as compared to first generation. Emerging data may permit even shorter duration; trials are awaited.

       
     
  12. 12.
    DAPT dose in chronic kidney disease:
    1. (a)
      Stages 1–3
      • EGFR >30 mL/min/1.73 m2
        • Aspirin: Loading at 150–300 mg orally, followed by maintenance 75 mg–100 mg/day

        • Clopidogrel: Loading at 300–600 mg orally, followed by 75 mg/day

        • Ticagrelor: Loading at 180 mg orally, followed by 90 mg BD/day

        • Prasugrel: Loading at 60 mg orally, followed by 10 mg/day

       
    2. (b)
      Stage 4
      • EGFR 15–30 mL/min/1.73 m2
        • No dose adjustment

       
    3. (c)
      Stage 5
      • EGFR <15 mL/min/1.73 m2
        • Aspirin: No dose adjustment

        • Clopidogrel: No information available

        • Ticagrelor and prasugrel: NOT recommended

       
     
  13. 13.

    Glycoprotein IIb/IIIa inhibitor usage in prehospital or upstream settings has not shown extra benefits on efficacy of treatment.

     
  14. 14.

    Selective downstream usage of GPIIb/IIIa inhibitors reduces cost of treatment and bleeding risk [15].

     
  15. 15.

    Usage of glycoprotein IIb/IIIa inhibitor during coronary catheterization as a bailout therapy can be considered. This includes large thrombus, slow or no reflow, or other findings of thrombotic complications during coronary angiogram [16].

     
  16. 16.

    Special patient subgroup.

     
Fig. 8.1

Switching of P2Y12 inhibitor product in acute setting [13]

Fig. 8.2

Bleeding risk assessment before deciding duration of dual antiplatelet therapy [14]

Fig. 8.3

Recommended duration of DAPT in patient undergoing PCI [14]

In patients on oral anticoagulation who present with STEMI and are undergoing emergency PCI, these patients should:
  1. (a)

    Loading of aspirin and clopidogrel (the P2Y12 inhibitor of choice, 600 mg loading dose) should be done.

     
  2. (b)

    Also receive additional parenteral anticoagulation.

     
  3. (c)

    Chronic oral anticoagulation therapy should not be stopped during admission.

     
  4. (d)

    Gastric protection with a proton pump inhibitor is recommended.

     
  5. (e)

    Triple therapy (oral anticoagulation, aspirin, and clopidogrel) should be considered for 6 months after STEMI.

     
  6. (f)

    Oral anticoagulation plus aspirin or clopidogrel should be considered for an additional 6 months; after which, it is then indicated to maintain oral anticoagulation.

     
  7. (g)

    For patients with atrial fibrillation as the indication for anticoagulation, rivaroxaban in combination with clopidogrel and without aspirin may be a reasonable choice.

     
  8. (h)

    The use of ticagrelor or prasugrel is not recommended as part of a triple therapy regimen with aspirin and oral anticoagulation.

     

8.6 Summary

  • DAPT is an important periprocedural pharmacotherapy in patient receiving PCI.

  • DAPT, aspirin, and a P2Y12 inhibitor are to be loaded orally as soon as diagnosis of ACS was made.

  • Choice of P2Y12 inhibitor includes prasugrel, ticagrelor, and clopidogrel.

  • Duration of DAPT treatment after emergency PCI depends on bleeding risk assessment and types of stents used.

  • Extra attention in cases with bioresorbable vascular scaffold, which requires at least 12 months of DAPT regardless of bleeding risk.

  • Glycoprotein IIb/IIIa inhibitor usage depends on treating physician justification as no conclusive evidence of its routine use in emergency PCI.

References

  1. 1.
    Patrono C, Bachmann F, Baigent C, Bode C, De Caterina R, Charbonnier B, et al. Expert consensus document on the use of antiplatelet agents: the task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European Society of Cardiology. Eur Heart J. 2004;25(2):166–81.CrossRefGoogle Scholar
  2. 2.
    Randomised trial of intravenous streptokinase, oral aspirin, both, or neither. among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2. (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2(8607):349–60.Google Scholar
  3. 3.
    Antithrombotic Trialists’ Collaboration, Trialists A. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324(7329):71–86. http://view.ncbi.nlm.nih.gov/pubmed/11786451 CrossRefGoogle Scholar
  4. 4.
    Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med. 1988;318(26)CrossRefGoogle Scholar
  5. 5.
    Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124(23)Google Scholar
  6. 6.
    Wallentin L. P2Y12 inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J. 2009;30(16):1964–77.CrossRefGoogle Scholar
  7. 7.
    Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patientsundergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527–33.CrossRefGoogle Scholar
  8. 8.
    Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM, RITON-TIMI 38 Investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373:723–31.CrossRefGoogle Scholar
  9. 9.
    Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, Kontny F, Lewis BS, Steg PG, Storey RF, Wojdyla D, Wallentin L, inhibition PLAT, Investigators p O. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375:283–93.CrossRefGoogle Scholar
  10. 10.
    Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes. Technology appraisal guidance [TA47]. Published date: 05 September 2002; Last updated: 01 March 2010. https://www.nice.org.uk/guidance/ta47.
  11. 11.
    The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956–61.CrossRefGoogle Scholar
  12. 12.
    Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation. 2000;101:2557–67.CrossRefGoogle Scholar
  13. 13.
    PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med. 1998;338:1488–97.CrossRefGoogle Scholar
  14. 14.
    Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol [internet]. 2016;68(10):1082–115.  https://doi.org/10.1016/j.jacc.2016.03.513.CrossRefGoogle Scholar
  15. 15.
    Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2017;70(12):1082. http://academic.oup.com/eurheartj/article/doi/10.1093/eurheartj/ehx393/4095042/2017-ESC-Guidelines-for-the-management-of-acute Google Scholar
  16. 16.
    De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H. Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. Am J Cardiol. 2011;107(2):198–203.  https://doi.org/10.1016/j.amjcard.2010.08.063.CrossRefPubMedGoogle Scholar

Copyright information

© The Author(s) 2018

<SimplePara><Emphasis Type="Bold">Open Access</Emphasis> This chapter is licensed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.</SimplePara> <SimplePara>The images or other third party material in this book are included in the book's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the book's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.</SimplePara>

Authors and Affiliations

  1. 1.Sarawak Heart CentreKota SamarahanMalaysia
  2. 2.Sarawak General HospitalKuchingMalaysia

Personalised recommendations